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−4,339,412) and E/P (Beta: −0.16) (p < 0.05 both). Final adjusted
R2: E: 0.937; P/d: 0.918; E/P: 0.906. CONCLUSIONS: trend is
the most signiﬁcant variable in the three models and when an
impact is statistically signiﬁcant, it seems not to present long-
term sustainability because these supply measures have a short-
term impact.
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OBJECTIVE: To distribute the total health spending in Spain for
the years 1980–2000 among the seventeen ICD-9-CM cate-
gories. The study aimed to gather data for 1980, 1985, 1990,
1993, 1996, and 2000 in order to obtain a baseline from which
to analyse the evolution of spending over time. METHODS: The
method used was the top-down approach, starting with overall
spending ﬁgures and, by means of various procedures, breaking
them down to the desired level. The method comprised two
stages. First, health spending was distributed according to the
different types of health care: hospital care, primary care, drugs,
and others. Second, the spending for each type of care was dis-
tributed among the ICD-9-CM categories. The base unit varied
according to each level: admissions for hospital care, appoint-
ments for primary care, and consumption per therapeutic sub-
group for drug treatment. RESULTS: In the period 1980–2000
health spending was concentrated into three ICD-9 categories:
VII, VIII and IX (37.4% of spending in 1980 and 40.1% of
spending in 2000). In terms of their relative rankings, category
VII was second in 1980 (10.1%) but had moved into ﬁrst place
by the year 2000 (17.6%), showing one of the highest growth
rates for the period. Category VIII (diseases of the respiratory
system) was ranked ﬁrst in 1980 (17.6%) but had fallen to
second place by 2000 (13.2%). As regards the third category (IX:
diseases of the digestive system) its relative position hardly
varied: 9.7% in 1980 and 9.3% in 2000. The results also show
that although the internal composition of each category (per-
centage of each type of health care) may vary widely, few im-
portant variations were observed between 1980 and 2000.
CONCLUSIONS: The information provided may be of use to
health managers and planners and it also establishes reference
baselines for cost-of-illness studies of speciﬁc pathologies.
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OBJECTIVES: The article is transversal comparison expenditure
analysis for drugs of 23 economicly developed european coun-
tries that are members of OECD. The data are related to year
2003, ﬁnancial indicators are expressed in dollars. METHODS:
Drug expenses are analysed in relation with those variables: GDP
per 1 inhabitant, health care expenses per 1 inhabitant, number
of physicians in praxis per 1000 inhabitants, proportion of
inhabitants of the age 65 years or more. Among all the variables
medium strong to strong relation was observed, determination
index between drug expenditure per 1 inhabitant and actual
number of active physicians and proportion of inhabitants of the
age 65 years or more reached the value of 51%. RESULTS:
Average drug expenditure per 1 inhabitant of the given year were
343 dollars, absolute average year growth in the years period
1995–2003, 19,4 dollars. Propotional expenditure average of
health care from GDP reached in the year 2003 value of 8,32%,
expenditure proportion on drugs from GDP was 1,37% from
health care expenditure 16,9%. By cluster analysis signiﬁcant
relation between drug expenditure and number of general physi-
cians and elderly inhabitants was determined. CONCLUSION:
Lower drug expenditures have countries with lower economical
efﬁciency, but also economicly developed European countries
where systemic regulations are applied, directed towards main
activators affecting the drug’s consumption and price.
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Until the late 1980s, the German health care machine worked
well. Since then, it has been challenged the restructuring of the
health care system of the former East Germany, economic down-
turn and changing demographics. OBJECTIVES: To analyze the
reforms in ﬁnancing and reimbursement in the German health
care system over the past 15 years to guide health reforms 
elsewhere. METHODS: A policy and evaluation analysis was
applied to the literature on health ﬁnancing reforms in Germany
to understand the contexts of the measures and their effects. To
understand the impact of the policies, a scale was developed to
assess the trajectory of the health care system as a result of the
reforms based on the principles of solidarity and subsidiarity on
which the German health care system was built. RESULTS: Clas-
siﬁcation of 12 reimbursement and ﬁnancing measures indicates
a shift away from the status quo from the solidarity-subsidiarity
dyad towards either the solidarity-governmental interference or
Eigenverantwortung (personal responsibility)-subsidiarity dyad.
Unfortunately, despite their collective potential of far-reaching
impact and long-term success, deﬁcit in operating mechanism(s)
and inconsistencies have hindered the supply-side cost-
containment measures of the past 15 years. CONCLUSION: Just
as a change in the environment requires new tools to address
challenges faced by the system, so does the approach to insti-
tuting reforms call for rethinking. While in the politics of health
policy evolutionary reforms may make more sense than radical
reforms, beyond evolutionary reforms which have produced only
modest results the sustainability of the ﬁnancing of the system
calls for radical reforms.
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OBJECTIVES: Analysis of utilization of the right to sick leaves
of the beneﬁciaries of the Republic Health Insurance Insti-
tute(RHII) in the period from January to September 2005, lasting
more that 30 days, analysis of the reasons for sick leaves and
suggested measures for more efﬁcient control over the rights to
beneﬁts, upgrading of utilization and guaranteeing the rights,
providing equal rights to all beneﬁciaries,and abuse reduction.
METHODS: Statistic data processing by uniform statistic forms
containing data on all medical commissions, classiﬁcation of
groups of deseases according to the ICD-10. RESULTS: The total
number of beneﬁciaries with temporary work disability was
263,825, 50,316 were enabled, 213,509 were given extensions
and 28,387 beneﬁciaries were sent to DMC. The most common
reasons for sick leaves were: vascular deseases 12.73%, bones,
joints & muscles system 11.36%, mental and behaviour disor-
ders 10.85%, injuries—distorsions and fractures 9.05%, tumors
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6.13%, pregnancy 5.57% and nervous system diseases 3.45%.
These groups of deseases are, by importance, the main cause of
absence from work in all the regions. The rate of sick leaves over
30 days for the entire territory of the Republic of Serbia is
7.06%. The point of interest here is that this rate is very uneven
in varous regions and amounts from 1.72% to 18.27%. The
total liabilities of RHII in the period from January to September
2005, for reimbursement of sick leaves were €56,732,175. CON-
CLUSIONS: Data obtained by this analysis illustrate that the
sick leave rate is very high and uneven, which is the result of
absence of medical doctrine standards for evaluation of tempo-
rary work disability. In addition, the most frequent reasons for
sick leaves are the effects of bad habits, poverty and risk factors:
smoking, lack of physical activity, overweight and generally poor
life quality and insufﬁcient protection at work by employers.
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OBJECTIVE: To analyze the price changes in the leading thera-
peutic groups and medicines after the introduction of the new
pricing schema in Serbia. METHODS: The legislative analysis of
the new pricing schema was applied on price changes. The
leading 10 medicines by therapeutic classes both in ﬁnancial
terms were chosen on the basis of the previous market analysis.
The relative share of price changes and waged price indexes were
calculated. RESULT: In 2005 the Ministry Council has issued the
new drug prices regulation that changes the pricing approach
from “cost+” to reference pricing. Italy, Croatia and Slovenia
were chosen for reference countries and prices have been com-
pared at wholesale level on the basis of different discounting per-
centages matching the local interest rate. The manufacturers
should provide a set of documents including pharmacoeconomic
analysis in free form for new price registration. The goal of the
pharmacoeconomic analysis should be to evaluate the impact of
the new price on the affordability. The market analysis revealed
that the leading ATC groups in ﬁnancial terms are cardiovascu-
lar medicines (C), anti infective (J), acting on muscles and bones
and anxiolytics (N) accounting for near 30% of the whole
market. After the introduction of the new pricing schema the
leading medicines in those ATC groups changed their character-
istics—group C quantities prescribed and total cost increased by
10,86% and 21,08% respectively; group J reduced quantity by
15,50% and increased value by 19,02%, group M reduce quan-
tity by 15,46% and total cost by 99, 40% and anxiolytic
increased quantity and total cost by 8,08% and 63,75% respec-
tively. CONCLUSION: New pricing schema lead to the increas-
ing usage of the most important medicines in value terms but has
controversial effect on quantities consumed.
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OBJECTIVES: To allocate an annual budget (2006) for each
primary care health team (PHCT) in relation to pharmaceutical
expenditure. METHODS: Three factors are considered in the
allocation formula: A capitation factor: allocation for insured
population based on real average costs per capita of the
autonomous community (7 million people) considering 20
isocost age bands. Pearson’s variation coefﬁcient was applied to
deﬁne isocost bands (criteria: PCV < 10% in each band). Gender
is also considered in this indirect standardization process. This
allocation value is increased by the monetary ﬂows generated by
not-assigned insured (other PHCT, other autonomous commu-
nities and foreigners) and subtracted by the pharmaceutical cost
service lent to their own insured population in other PHCT. This
capitation factor is increased in the coefﬁcient of global growth
expenditure established for 2006 (4%). Modulator factor con-
siders the number of old people’s homes managed, the variation
of insured population during last year and the value of the rate
of use (Pearson’s correlation coefﬁcient between standardised
expenditure per inhabitant and the rate of use is 53% (p < 0.05)).
Finally an adjustment factor is applied in order to establish a
temporal horizon. Three PHCT groups (33–66 percentiles) are
deﬁned according to deviations in relation to real expenditure
for 2005 (normal distribution: p > 0.1 in Z-Kolmogorov
Smirnov). For every group a minimum and maximum increase
is determined, maintaining the order and the global increase
established for all the PHCTs (4%). RESULTS: considering pop-
ulation structure for each PHCT makes possible to obtain allo-
cations per capita between €157–350. For 99% of PHCT,
modulator factor doesn’t represent an impact above +/−20%
over capitation factor. For each PHCT, ﬁnal allocation represents
an increase between 2%-6.25% on pharmaceutical expenditure
of 2005. CONCLUSION: The model leaves behind historical
models of growth, and establishes a high degree of responsibil-
ity to PHCTs in relation to pharmaceutical expenditure.
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OBJECTIVES: Diagnostic x-ray procedures using contrast
imaging agents especially in CT are on the rise. Typically con-
trast media are available in glass bottles and associated with a
number of potential problems including increased risk of injury,
costs of waste disposal, lost revenue, and disturbances in depart-
ment routines. A model was developed to estimate the annual
ﬁnancial and safety impact of switching glass to a polymer con-
tainer for a typical radiology department. METHODS: The
model was developed using results from a multi-European
market survey of radiology technologists on rates of technolo-
gists’ injuries from glass and/or metal crimps and from bottle
breaks. Survey results were conﬁrmed by a radiology department
head from a UK community hospital. In addition, disposal costs
for waste, acquisition cost of contrast media, utilization patterns
of media, procedure rates, technologist salaries, and cost of dis-
turbed department routine were incorporated in the ﬁnal budget
comparison. RESULTS: For a typical community hospital in the
UK conducting 56 procedures per shift, there is a potential to
waste approximately 200 manpower hours for clean-up of glass
breaks, injury care, and setting up additional contrast imaging
sets. This is associated with annual revenue loss to a department.
Budgetary gains are noted in lower disposal costs for polymer
bottles as they are lighter in weight. Signiﬁcantly more disposal
costs gains would be noted with the implementation of separat-
ing hazardous from regular waste. PLUSPAK, a polymer bottle
containing iohexol, a low osmolar contrast medium, has the
potential to save a radiology department considerable savings
due to cost-offsets associated with lower injury rates, product
wastage, disposal waste costs and faster departmental efﬁcien-
cies. CONCLUSIONS: Improvements in radiology technologist
